Primary hyperoxaluria

New England Journal of Medicine

Volumn 369, Issue 7, 2013, Pages 649-658

  Cochat, Pierre ^a   Rumsby, Gill ^b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM OXALATE; CREATININE; GLYCERIC ACID; GLYCINE; GLYCOLIC ACID; GLYOXYLIC ACID; ISOLEUCINE; LACTATE DEHYDROGENASE; LEUCINE; OXALIC ACID; PARVOVIRUS VECTOR; PHENYLALANINE; PROLINE; PYRIDOXINE; THREONINE;

ACUTE KIDNEY FAILURE; CALCIUM OXALATE STONE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESPONSE; EXTRACORPOREAL LITHOTRIPSY; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEPATOCYTE TRANSPLANTATION; HUMAN; HYPEROXALURIA; INCIDENCE; KIDNEY CALCIFICATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; METABOLIC ACIDOSIS; NONHUMAN; OXALOSIS 1; PERITONEAL DIALYSIS; PRENATAL DIAGNOSIS; PREVALENCE; PRIMARY HYPEROXALURIA TYPE 2; PRIMARY HYPEROXALURIA TYPE 3; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SUPPLEMENTATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84881416930     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1301564     Document Type: Review

References (72)

1. Lepoutre C. Calculs multiples chez un enfant: Infiltration du parenchyme rénal par des dépôts cristallins. J Urol 1925;20:424.
2. Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 2013;123:236-46.
3. Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999;56:268-74. (Pubitemid 29300544)
4. Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N. Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant 1995;10:Suppl 8:3-7.
5. van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in the Netherlands: prevalence and outcome. Nephrol Dial Transplant 2003;18:273-9. (Pubitemid 36181676)
6. Harambat J, van Stralen KJ, Espinosa L, et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 2012;7:458-65.
7. Kamoun A, Lakhoua R. End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome. Pediatr Nephrol 1996;10:479-82. (Pubitemid 26261606)
8. Zhang X, Roe SM, Pearl LH, Danpure CJ. Crystallization and preliminary crystallographic analysis of human alanine: glyoxylate aminotransferase and its polymorphic variants. Acta Crystallogr D Biol Crystallogr 2001;57:1936-7. (Pubitemid 33145627)
9. Cregeen DP, Williams EL, Hulton SA, Rumsby G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 2003;22:497.
10. Behnam JT, Williams EL, Brink S, Rumsby G, Danpure CJ. Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells. Biochem J 2006;394:409-16. (Pubitemid 43342541)
11. Baker PRS, Cramer SD, Kennedy M, Assimos DG, Holmes RP. Glycolate and glyoxylate metabolism in HepG2 cells. Am J Physiol Cell Physiol 2004;287:C1359-C1365. (Pubitemid 39382895)
12. Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010;87:392-9.
13. Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One 2011;6(10):e26021.
14. Belostotsky R, Pitt JJ, Frishberg Y. Primary hyperoxaluria type III - a model for studying perturbations in glyoxylate metabolism. J Mol Med (Berl) 2012;90:1497-504.
15. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 2012;1822:1544-52.
16. Rumsby G. An overview of the role of genotyping in the diagnosis of the primary hyperoxalurias. Urol Res 2005;33:318-20. (Pubitemid 41752053)
17. Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate amino-transferase encoded by the polymorphic minor allele. J Biol Chem 2013;288:2475-84.
18. Rumsby G. Primary hyperoxaluria database (http://www.uclh.nhs.uk/phmd).
19. Williams EL, Acquaviva C, Amoroso A, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 2009;30:910-7.
20. Benhaj Mbarek I, Abroug S, Omezzine A, et al. Selected AGXT gene mutations analysis provides a genetic diagnosis in 28% of Tunisian patients with primary hyperoxaluria. BMC Nephrol 2011;12:25.
21. Santana A, Salido E, Torres A, Shapiro LJ. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci U S A 2003;100:7277-82. (Pubitemid 36706429)
22. Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005;67:1704-9. (Pubitemid 40577704)
23. Harambat J, Fargue S, Acquaviva C, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 2010;77:443-9.
24. Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 2013;1832:1776-83.
25. Frishberg Y, Rinat C, Shalata A, et al. Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Am J Nephrol 2005;25:269-75. (Pubitemid 41202750)
26. Williams EL, Bockenhauer D, van't Hoff WG, et al. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 2012;27:3191-5.
27. Beck BB, Baasner A, Buescher A, et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 2013;21:162-72.
28. Monico CG, Rossetti S, Belostotsky R, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 2011;6:2289-95.
29. Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol 2005;25:290-6. (Pubitemid 41202753)
30. van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant 2012;27:3855-62.
31. Punjabi OS, Riaz K, Mets MB. Crystalline retinopathy in primary hyperoxaluria. J AAPOS 2011;15:214-6.
32. Bakshi NA, Al-Zahrani H. Bone marrow oxalosis. Blood 2012;120:8.
33. Mookadam F, Smith T, Jiamsripong P, et al. Cardiac abnormalities in primary hyperoxaluria. Circ J 2010;74:2403-9.
34. Beck BB, Hoyer-Kuhn H, Göbel H, Habbig S, Hoppe B. Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs 2013;22:117-29.
35. Bergstralh EJ, Monico CG, Lieske JC, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant 2010;10:2493-501.
36. van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJA, Waterham HR. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 2004;66:746-52. (Pubitemid 38982018)
37. Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001;59:31-6. (Pubitemid 32055211)
38. Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol 2005;25:154-60. (Pubitemid 40864184)
39. Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012;27:1729-36.
40. Daudon M, Estepa L, Lacour B, Jungers P. Unusual morphology of calcium oxalate calculi in primary hyperoxaluria. J Nephrol 1998;11:Suppl 1:51-5. (Pubitemid 28218918)
41. Daudon M, Jungers P, Bazin D. Peculiar morphology of stones in primary hyperoxaluria. N Engl J Med 2008;359:100-2. (Pubitemid 351931124)
42. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2012;8:467-75.
43. Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 1991;66:501-3.
44. Dietzen DJ, Wilhite TR, Kenagy DN, Milliner DS, Smith CH, Landt M. Extraction of glyceric and glycolic acids from urine with tetrahydrofuran: utility in detection of primary hyperoxaluria. Clin Chem 1997;43:1315-20. (Pubitemid 27329775)
45. Williams HE, Smith LH. The identification and determination of glyceric acid in human urine. J Lab Clin Med 1968;71:495-500.
46. Rumsby G, Sharma A, Cregeen DP, Solomon LR. Primary hyperoxaluria type 2 without L-glycericaciduria: is the disease under-diagnosed? Nephrol Dial Transplant 2001;16:1697-9. (Pubitemid 32750467)
47. Rumsby G. Experience in prenatal diagnosis of primary hyperoxaluria type 1. J Nephrol 1998;11:Suppl 1:13-4. (Pubitemid 28218908)
48. Fargue S, Harambat J, Gagnadoux MF, et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 2009;76:767-73.
49. Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 2004;72:Suppl 1:6-10. (Pubitemid 38608354)
50. Sikora P, von Unruh GE, Beck B, et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008;73:1181-6. (Pubitemid 351620437)
51. Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011;300:G461-G469.
52. Hoppe B, Groothoff JW, Hulton SA, et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011;26:3609-15.
53. Pais VM Jr, Assimos DG. Pitfalls in the management of patients with primary hyperoxaluria: a urologist's perspective. Urol Res 2005;33:390-3. (Pubitemid 41752063)
54. Al-Abadi E, Hulton SA. Extracorporeal shock wave lithotripsy in the management of stones in children with oxalosis - still the first choice? Pediatr Nephrol 2013;28:1085-9.
55. Blomgren PM, Connors BA, Lingeman JE, Willis LR, Evan AP. Quantitation of shock wave lithotripsy-induced lesion in small and large pig kidneys. Anat Rec 1997;249:341-8. (Pubitemid 27469285)
56. Straub M, Gschwend J, Zorn C. Pediatric urolithiasis: the current surgical management. Pediatr Nephrol 2010;25:1239-44.
57. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 2006;70:1642-8. (Pubitemid 44607001)
58. Hoppe B, Kemper MJ, Bökenkamp A, Langman CB. Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int 1998;54:921-5. (Pubitemid 28397410)
59. Sahin G, Acikalin MF, Yalcin AU. Erythropoietin resistance as a result of oxalosis in bone marrow. Clin Nephrol 2005;63:402-4. (Pubitemid 40668236)
60. Bacchetta J, Fargue S, Boutroy S, et al. Bone metabolism in oxalosis: a singlecenter study using new imaging techniques and biomarkers. Pediatr Nephrol 2010;25:1081-9.
61. Kemper MJ, Nolkemper D, Rogiers X, et al. Preemptive liver transplantation in primary hyperoxaluria type 1: timing and preliminary results. J Nephrol 1998;11:Suppl 1:46-8. (Pubitemid 28218916)
62. Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 2013 March 14 (Epub ahead of print).
63. Jamieson NV. The results of combined liver/kidney transplantation for primary hyperoxaluria (PH1) 1984-1997: the European PH1 transplant registry report. J Nephrol 1998;11:Suppl 1:36-41. (Pubitemid 28218914)
64. Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hernández D, Salido EC. Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: single-center experience. Kidney Int 2006;70:1115-9. (Pubitemid 44344082)
65. Malla I, Lysy PA, Godefroid N, et al. Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation. Pediatr Transplant 2009;13:782-4.
66. Mor E, Nesher E, Ben-Ari Z, et al. Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 2013;19:646-8.
67. Salido EC, Li XM, Lu Y, et al. Alanine-glyoxylate aminotransferase- deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A 2006;103:18249-54. (Pubitemid 44871644)
68. Knight J, Holmes RP, Cramer SD, Takayama T, Salido E. Hydroxyproline metabolism in mouse models of primary hyperoxaluria. Am J Physiol Renal Physiol 2012;302:F688-F693.
69. Jiang J, Salido EC, Guha C, et al. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation 2008;85:1253-60. (Pubitemid 351670473)
70. Guha C, Yamanouchi K, Jiang J, et al. Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. Am J Nephrol 2005;25:161-70. (Pubitemid 40864185)
71. Beck BB, Habbig S, Dittrich K, et al. Liver cell transplantation in severe infantile oxalosis - a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant 2012;27:2984-9.
72. Hopper ED, Pittman AMC, Fitzgerald MC, Tucker CL. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase. J Biol Chem 2008;283:30493-502.